Business Description
This fund puts the large majority of its money into companies from both developed and emerging markets that stand to gain from advances in genomics, immunology, and bioengineering. A smaller portion may be held in futures, options, swap contracts, or cash. The fund focuses on a single area of the market and is therefore considered non-diversified.
